_id,cohorts.0.id,cohorts.0.label,dataUseConditions.id,dataUseConditions.label,description,externalReferences.0.id,externalReferences.0.label,histologicalDiagnosis.id,histologicalDiagnosis.label,icdoMorphology.id,icdoMorphology.label,icdoTopography.id,icdoTopography.label,id,individualId,info.callsetIds.0,info.cnvstatistics.cnvcoverage,info.cnvstatistics.cnvfraction,info.cnvstatistics.delcoverage,info.cnvstatistics.delfraction,info.cnvstatistics.dupcoverage,info.cnvstatistics.dupfraction,info.legacyId.0,pathologicalStage,provenance.geoLocation.geometry.coordinates.0,provenance.geoLocation.geometry.coordinates.1,provenance.geoLocation.geometry.type,provenance.geoLocation.properties.ISO3166alpha3,provenance.geoLocation.properties.city,provenance.geoLocation.properties.country,provenance.geoLocation.properties.label,provenance.geoLocation.properties.latitude,provenance.geoLocation.properties.longitude,provenance.geoLocation.properties.precision,provenance.geoLocation.type,provenance.material.id,provenance.material.label,sampledTissue.id,sampledTissue.label,tumorGrade,updated,externalReferences.1.id,externalReferences.1.label,individualAgeAtCollection,cohorts.1.id,cohorts.1.label,info.tnm,pathologicalStage.id,pathologicalStage.label,pathologicalTnmFindings.0.id,pathologicalTnmFindings.0.label,pathologicalTnmFindings.1.id,pathologicalTnmFindings.1.label,info.death,info.followupMonths,pathologicalTnmFindings.2.id,pathologicalTnmFindings.2.label,tumorGrade.id,tumorGrade.label,cohorts.2.id,cohorts.2.label,externalReferences.0.description,externalReferences.1.description,externalReferences.2.description,externalReferences.2.id,externalReferences.2.label,info.tumorStage,cohorts.3.id,cohorts.3.label,info.callsetIds.1,externalReferences.3.description,externalReferences.3.id,externalReferences.3.label,info.provenance,provenance.populations.0.confidence,provenance.populations.0.description,provenance.populations.0.type.id,provenance.populations.0.type.label,provenance.populations.1.confidence,provenance.populations.1.description,provenance.populations.1.type.id,provenance.populations.1.type.label,pathologicalTnmFindings.3.id,pathologicalTnmFindings.3.label,cohorts.4.id,cohorts.4.label,externalReferences.4.description,externalReferences.4.id,externalReferences.4.label,info.samplesource,info.seer,info.cellLine,ageAtCollection.age,ageAtCollection.ageClass.id,ageAtCollection.ageClass.label,projectId,sex
5bab56c7727983b2e00ae4a2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzpr,pgxind-kftx2tf8,pgxcs-kftvr99e,341481997,0.119,120070128,0.042,221411869,0.077,PGX_AM_BS_BrCa-fri-S0001,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.016000,,,P61Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzps,pgxind-kftx2tfa,pgxcs-kftvr99w,1451124880,0.505,960481735,0.334,490643145,0.171,PGX_AM_BS_BrCa-fri-S0013,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.017000,,,P48Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzpu,pgxind-kftx2tfc,pgxcs-kftvr9ad,508629525,0.177,331567340,0.115,177062185,0.062,PGX_AM_BS_BrCa-fri-S0021,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.019000,,,P70Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,0,98,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzpw,pgxind-kftx2tfe,pgxcs-kftvr9au,1566353468,0.545,974331973,0.339,592021495,0.206,PGX_AM_BS_BrCa-fri-S0024,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.020000,,,P71Y,,,,,,,,,,0,118,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzpx,pgxind-kftx2tfh,pgxcs-kftvr9bc,244799252,0.085,148367152,0.052,96432100,0.034,PGX_AM_BS_BrCa-fri-S0033,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.021000,,,P71Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,0,137,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzpz,pgxind-kftx2tfj,pgxcs-kftvr9bt,978345997,0.34,577857588,0.201,400488409,0.139,PGX_AM_BS_BrCa-fri-S0041,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.023000,,,P39Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4af,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqc,pgxind-kftx2tfz,pgxcs-kftvr9hh,1391130609,0.484,737562751,0.257,653567858,0.227,PGX_AM_BS_BrCa-fri-S0066,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.034000,,,P80Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqd,pgxind-kftx2tg0,pgxcs-kftvr9hz,42943044,0.015,0,0,42943044,0.015,PGX_AM_BS_BrCa-fri-S0071,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.035000,,,P39Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,60,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqg,pgxind-kftx2tg4,pgxcs-kftvr9iy,449157457,0.156,72525075,0.025,376632382,0.131,PGX_AM_BS_BrCa-fri-S0077,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.038000,,,P51Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqi,pgxind-kftx2tg6,pgxcs-kftvr9jf,840174744,0.292,197545201,0.069,642629543,0.224,PGX_AM_BS_BrCa-fri-S0081,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.039000,,,P78Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqk,pgxind-kftx2tg8,pgxcs-kftvr9jw,1134027479,0.394,624278319,0.217,509749160,0.177,PGX_AM_BS_BrCa-fri-S0104,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.041000,,,P72Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,147,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzql,pgxind-kftx2tga,pgxcs-kftvr9ke,243083251,0.085,106402112,0.037,136681139,0.048,PGX_AM_BS_BrCa-fri-S0117,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.042000,,,P84Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,59,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqp,pgxind-kftx2tge,pgxcs-kftvr9lc,1065157615,0.37,617907972,0.215,447249643,0.156,PGX_AM_BS_BrCa-fri-S0126,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.045000,,,P70Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,0,111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqs,pgxind-kftx2tgi,pgxcs-kftvr9ma,948070850,0.33,704678961,0.245,243391889,0.085,PGX_AM_BS_BrCa-fri-S0132,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.048000,,,P83Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,0,92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr9,pgxind-kftx2th4,pgxcs-kftvr9rm,332941340,0.116,242697249,0.084,90244091,0.031,PGX_AM_BS_BrCa-fri-S0303,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.063000,,,P39Y,,,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,0,91,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrb,pgxind-kftx2th6,pgxcs-kftvr9s3,308981304,0.107,4345006,0.002,304636298,0.106,PGX_AM_BS_BrCa-fri-S0304,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.064000,,,P41Y,,,,,,,,,,0,130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrd,pgxind-kftx2th8,pgxcs-kftvr9sk,531830547,0.185,0,0,531830547,0.185,PGX_AM_BS_BrCa-fri-S0385,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.066000,,,P37Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,0,126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzre,pgxind-kftx2tha,pgxcs-kftvr9t1,443800089,0.154,163936168,0.057,279863921,0.097,PGX_AM_BS_BrCa-fri-S0394,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.067000,,,P43Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,83,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrg,pgxind-kftx2thc,pgxcs-kftvr9tj,1109968010,0.386,653717915,0.227,456250095,0.159,PGX_AM_BS_BrCa-fri-S1503,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.068000,,,P49Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrh,pgxind-kftx2the,pgxcs-kftvr9u1,104298106,0.036,8780010,0.003,95518096,0.033,PGX_AM_BS_BrCa-fri-S1504,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.070000,,,P45Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,76,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ca,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrj,pgxind-kftx2thg,pgxcs-kftvr9ui,105986111,0.037,68085072,0.024,37901039,0.013,PGX_AM_BS_BrCa-fri-S1506,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.071000,,,P51Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,80,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4cb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrk,pgxind-kftx2thi,pgxcs-kftvr9uz,656566674,0.228,302385310,0.105,354181364,0.123,PGX_AM_BS_BrCa-fri-S1508,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.072000,,,P44Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,83,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4cc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrm,pgxind-kftx2thk,pgxcs-kftvr9vh,561514106,0.195,449018988,0.156,112495118,0.039,PGX_AM_BS_BrCa-fri-S1511,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.074000,,,P48Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ce,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrp,pgxind-kftx2tho,pgxcs-kftvr9wg,458425464,0.159,108928110,0.038,349497354,0.122,PGX_AM_BS_BrCa-fri-S1519,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.077000,,,P89Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,34,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrs,pgxind-kftx2ths,pgxcs-kftvr9xf,136549138,0.047,41031042,0.014,95518096,0.033,PGX_AM_BS_BrCa-fri-S1523,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.080000,,,P83Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrw,pgxind-kftx2thw,pgxcs-kftvr9ye,79367083,0.028,0,0,79367083,0.028,PGX_AM_BS_BrCa-fri-S1526,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.083000,,,P73Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrx,pgxind-kftx2thz,pgxcs-kftvr9yv,446405095,0.155,91328095,0.032,355077000,0.124,PGX_AM_BS_BrCa-fri-S1534,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.084000,,,P94Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzrz,pgxind-kftx2ti1,pgxcs-kftvr9zc,247259256,0.086,100815103,0.035,146444153,0.051,PGX_AM_BS_BrCa-fri-S1536,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.086000,,,P83Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs0,pgxind-kftx2ti3,pgxcs-kftvr9zu,539863016,0.188,231951803,0.081,307911213,0.107,PGX_AM_BS_BrCa-fri-S1539,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.087000,,,P42Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs2,pgxind-kftx2ti5,pgxcs-kftvra0b,176380179,0.061,41031042,0.014,135349137,0.047,PGX_AM_BS_BrCa-fri-S1541,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.088000,,,P51Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,61,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs4,pgxind-kftx2ti7,pgxcs-kftvra0t,1011172004,0.352,918909904,0.32,92262100,0.032,PGX_AM_BS_BrCa-fri-S1542,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.090000,,,P77Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs5,pgxind-kftx2ti9,pgxcs-kftvra1a,125180131,0.044,122463127,0.043,2717004,0.001,PGX_AM_BS_BrCa-fri-S1545,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.091000,,,P40Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs7,pgxind-kftx2tib,pgxcs-kftvra1s,683695868,0.238,38815040,0.014,644880828,0.224,PGX_AM_BS_BrCa-fri-S1551,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.093000,,,P53Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,50,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4da,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzs8,pgxind-kftx2tid,pgxcs-kftvra29,0,0,0,0,0,0,PGX_AM_BS_BrCa-fri-S1572,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.094000,,,P78Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4db,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzsa,pgxind-kftx2tif,pgxcs-kftvra2q,333558980,0.116,164216170,0.057,169342810,0.059,PGX_AM_BS_BrCa-fri-S1575,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.095000,,,P79Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,49,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4dc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzsc,pgxind-kftx2tih,pgxcs-kftvra38,1271926757,0.442,639201659,0.222,632725098,0.22,PGX_AM_BS_BrCa-fri-S1579,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.097000,,,P46Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,71,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4dd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzsd,pgxind-kftx2tij,pgxcs-kftvra3p,578500237,0.201,193474836,0.067,385025401,0.134,PGX_AM_BS_BrCa-fri-S1598,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.098000,,,P74Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,0,40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4de,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzsf,pgxind-kftx2til,pgxcs-kftvra47,159411163,0.055,41031042,0.014,118380121,0.041,PGX_AM_BS_BrCa-fri-S1608,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.100000,,,P89Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,0,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add70,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx36,pgxind-kftx2qka,pgxcs-kftvqjh0,915822485,0.319,416779004,0.145,499043481,0.174,PGX_AM_BS_NCBISKYCGH-4330,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.084000,,,P50Y,,,T2N0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add71,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx37,pgxind-kftx2qkc,pgxcs-kftvqjhh,300988657,0.105,99100098,0.034,201888559,0.07,PGX_AM_BS_NCBISKYCGH-4331,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.085000,,,P43Y,,,T2N0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add72,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx39,pgxind-kftx2qke,pgxcs-kftvqjhy,0,0,0,0,0,0,PGX_AM_BS_NCBISKYCGH-4332,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.087000,,,P64Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add74,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3c,pgxind-kftx2qki,pgxcs-kftvqjix,976413228,0.34,531585650,0.185,444827578,0.155,PGX_AM_BS_NCBISKYCGH-4335,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.090000,,,P57Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add77,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3h,pgxind-kftx2qko,pgxcs-kftvqjm6,1001345566,0.348,504462881,0.175,496882685,0.173,PGX_AM_BS_NCBISKYCGH-4338,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.094000,,,P58Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add78,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3j,pgxind-kftx2qkq,pgxcs-kftvqjmo,1562872801,0.544,425796971,0.148,1137075830,0.396,PGX_AM_BS_NCBISKYCGH-4339,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.095000,,,P57Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add79,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3k,pgxind-kftx2qks,pgxcs-kftvqjn6,1348296947,0.469,550936011,0.192,797360936,0.277,PGX_AM_BS_NCBISKYCGH-4340,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.096000,,,P70Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add7b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3o,pgxind-kftx2qkw,pgxcs-kftvqjo6,794339208,0.276,304036607,0.106,490302601,0.171,PGX_AM_BS_NCBISKYCGH-4342,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.099000,,,P71Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add7e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3t,pgxind-kftx2ql2,pgxcs-kftvqjpm,1080586727,0.376,546447555,0.19,534139172,0.186,PGX_AM_BS_NCBISKYCGH-4345,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.104000,,,P43Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add7f,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx3u,pgxind-kftx2ql4,pgxcs-kftvqjq5,1875020687,0.652,667977459,0.232,1207043228,0.42,PGX_AM_BS_NCBISKYCGH-4346,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.105000,,,P63Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add89,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx4b,pgxind-kftx2qlo,pgxcs-kftvqjv2,0,0,0,0,0,0,PGX_AM_BS_NCBISKYCGH-4356,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.119000,,,P59Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add93,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx4r,pgxind-kftx2qm8,pgxcs-kftvqjzx,1336432495,0.465,610610664,0.212,725821831,0.252,PGX_AM_BS_NCBISKYCGH-4367,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.133000,,,P47Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add96,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx4x,pgxind-kftx2qme,pgxcs-kftvqk1d,1523209841,0.53,500522646,0.174,1022687195,0.356,PGX_AM_BS_NCBISKYCGH-4370,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.137000,,,P54Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add98,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx50,pgxind-kftx2qmi,pgxcs-kftvqk2c,1477028802,0.514,677736232,0.236,799292570,0.278,PGX_AM_BS_NCBISKYCGH-4375,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.140000,,,P48Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00add9e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx5a,pgxind-kftx2qmu,pgxcs-kftvqk58,1473591857,0.513,938877057,0.327,534714800,0.186,PGX_AM_BS_NCBISKYCGH-4381,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.149000,,,P33Y,,,T2N0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c6727983b2e00adda9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Infiltrating duct carcinoma, NOS",PMID:17213022,"Karlsson E, Danielsson A et al. (2007): Chromosomal changes associated with clinical outcome...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgx5s,pgxind-kftx2qnf,pgxcs-kftvqkaj,1155068610,0.402,407786244,0.142,747282366,0.26,PGX_AM_BS_NCBISKYCGH-4398,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:24.164000,,,P70Y,,,T1N0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48720,T1 Stage Finding,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzq1,pgxind-kftx2tfl,pgxcs-kftvr9cb,756341041,0.263,259646271,0.09,496694770,0.173,PGX_AM_BS_BrCa-fri-S0043,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.024000,,,P73Y,,,,,,,,,,1,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4a9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzq2,pgxind-kftx2tfn,pgxcs-kftvr9cs,587332246,0.204,246783893,0.086,340548353,0.118,PGX_AM_BS_BrCa-fri-S0050,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.025000,,,P86Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ab,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzq5,pgxind-kftx2tfr,pgxcs-kftvr9dr,727600939,0.253,247055254,0.086,480545685,0.167,PGX_AM_BS_BrCa-fri-S0052,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.028000,,,P79Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ac,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzq7,pgxind-kftx2tft,pgxcs-kftvr9e8,1922243296,0.669,1152816860,0.401,769426436,0.268,PGX_AM_BS_BrCa-fri-S0055,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.030000,,,P46Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,60,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ad,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzq8,pgxind-kftx2tfv,pgxcs-kftvr9ep,16590021,0.006,0,0,16590021,0.006,PGX_AM_BS_BrCa-fri-S0059,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.031000,,,P35Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4b1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqf,pgxind-kftx2tg2,pgxcs-kftvr9ih,907810734,0.316,230176853,0.08,677633881,0.236,PGX_AM_BS_BrCa-fri-S0073,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.036000,,,P78Y,,,,,,,,,,1,32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4ba,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqt,pgxind-kftx2tgk,pgxcs-kftvr9ms,564560475,0.196,371480636,0.129,193079839,0.067,PGX_AM_BS_BrCa-fri-S0136,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.049000,,,P36Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4bb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqv,pgxind-kftx2tgm,pgxcs-kftvr9n9,2121457380,0.738,1246624885,0.434,874832495,0.304,PGX_AM_BS_BrCa-fri-S0184,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.050000,,,P35Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,245,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4bc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqx,pgxind-kftx2tgo,pgxcs-kftvr9nr,361937921,0.126,76757082,0.027,285180839,0.099,PGX_AM_BS_BrCa-fri-S0195,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.052000,,,P31Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,49,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4bd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzqy,pgxind-kftx2tgq,pgxcs-kftvr9o8,1372217423,0.477,675348509,0.235,696868914,0.242,PGX_AM_BS_BrCa-fri-S0203,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.053000,,,P70Y,,,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4be,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, pre menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr0,pgxind-kftx2tgs,pgxcs-kftvr9op,609650271,0.212,116882124,0.041,492768147,0.171,PGX_AM_BS_BrCa-fri-S0221,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.055000,,,P37Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr3,pgxind-kftx2tgw,pgxcs-kftvr9po,472585105,0.164,272407265,0.095,200177840,0.07,PGX_AM_BS_BrCa-fri-S0252,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.057000,,,P76Y,,,,,,,,,,1,49,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr5,pgxind-kftx2tgy,pgxcs-kftvr9q5,17957021,0.006,17957021,0.006,0,0,PGX_AM_BS_BrCa-fri-S0256,{},-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.059000,,,P76Y,,,,,,,,,,1,49,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr6,pgxind-kftx2th0,pgxcs-kftvr9qn,708692910,0.247,402302590,0.14,306390320,0.107,PGX_AM_BS_BrCa-fri-S0257,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.060000,,,P41Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4c3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzr8,pgxind-kftx2th2,pgxcs-kftvr9r4,961245593,0.334,665352305,0.231,295893288,0.103,PGX_AM_BS_BrCa-fri-S0269,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.062000,,,P71Y,,,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4cd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERpos, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzro,pgxind-kftx2thm,pgxcs-kftvr9vy,1135344046,0.395,265311272,0.092,870032774,0.303,PGX_AM_BS_BrCa-fri-S1515,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.075000,,,P85Y,,,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,1,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4d1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzru,pgxind-kftx2thu,pgxcs-kftvr9xx,286104814,0.1,30530986,0.011,255573828,0.089,PGX_AM_BS_BrCa-fri-S1524,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.081000,,,P29Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5bab56c7727983b2e00ae4df,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"breast carcinoma [ductal invasive, ERneg, post menopause]",PMID:16620391,"Fridlyand J, Snijders AM et al. (2006): Breast tumor copy number aberration phenotypes...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvgzsh,pgxind-kftx2tin,pgxcs-kftvra4o,206517205,0.072,42080043,0.015,164437162,0.057,PGX_AM_BS_BrCa-fri-S1616,,-122.42,37.77,Point,USA,San Francisco,United States of America,"San Francisco, United States",37.77,-122.42,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:44:27.101000,,,P72Y,,,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa376,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514572,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu8o,pgxind-kftx4l8q,pgxcs-kftwbrbn,51277444,0.018,9305377,0.003,41972067,0.015,PGX_AM_BS_GSM514572,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.379000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,89,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,,,,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa377,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu8q,pgxind-kftx4l8s,pgxcs-kftwbrdo,35816474,0.012,3149740,0.001,32666734,0.011,PGX_AM_BS_GSM514573,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.381000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,47,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514573,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa379,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu8t,pgxind-kftx4l8w,pgxcs-kftwbre6,713374794,0.248,361300684,0.126,352074110,0.122,PGX_AM_BS_GSM514574,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.384000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,79,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514574,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa37c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu8z,pgxind-kftx4l92,pgxcs-kftwbrg3,150690305,0.052,131298658,0.046,19391647,0.007,PGX_AM_BS_GSM514578,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.388000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,98,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514578,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa37e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu92,pgxind-kftx4l96,pgxcs-kftwbrh2,1071794919,0.373,649797138,0.226,421997781,0.147,PGX_AM_BS_GSM514580,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.391000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,20,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514580,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa380,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu95,pgxind-kftx4l9a,pgxcs-kftwbri1,719752435,0.25,417605352,0.145,302147083,0.105,PGX_AM_BS_GSM514582,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.394000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,49,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514582,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa386,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514588,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9g,pgxind-kftx4l9m,pgxcs-kftwbrkw,70988507,0.025,17347427,0.006,53641080,0.019,PGX_AM_BS_GSM514588,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.403000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,67,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa387,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9h,pgxind-kftx4l9o,pgxcs-kftwbrld,295418199,0.103,116223882,0.04,179194317,0.062,PGX_AM_BS_GSM514589,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.404000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,100,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514589,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa389,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514591,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9l,pgxind-kftx4l9s,pgxcs-kftwbrmb,482980814,0.168,357455262,0.124,125525552,0.044,PGX_AM_BS_GSM514591,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.407000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,91,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL9077,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38a,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514592,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9m,pgxind-kftx4l9u,pgxcs-kftwbrmt,172415225,0.06,129668879,0.045,42746346,0.015,PGX_AM_BS_GSM514592,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.408000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,73,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514593,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9o,pgxind-kftx4l9w,pgxcs-kftwbrnb,443872333,0.154,159343622,0.055,284528711,0.099,PGX_AM_BS_GSM514593,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.410000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,66,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514594,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9q,pgxind-kftx4l9y,pgxcs-kftwbrnt,416126998,0.145,205661333,0.072,210465665,0.073,PGX_AM_BS_GSM514594,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.411000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,84,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9r,pgxind-kftx4la0,pgxcs-kftwbrob,558483182,0.194,361374106,0.126,197109076,0.069,PGX_AM_BS_GSM514595,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.413000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,1,6,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514595,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514596,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9t,pgxind-kftx4la2,pgxcs-kftwbrot,433836946,0.151,195008024,0.068,238828922,0.083,PGX_AM_BS_GSM514596,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.414000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,75,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gse,geo:GSE20483,,,,,,geo:gpl,geo:GPL9077,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa38f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9v,pgxind-kftx4la4,pgxcs-kftwbrpb,272570057,0.095,130043445,0.045,142526612,0.05,PGX_AM_BS_GSM514597,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.416000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,25,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514597,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614309d374f2dc3aa391,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514599,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviu9y,pgxind-kftx4la8,pgxcs-kftwbrq9,805825457,0.28,473421700,0.165,332403757,0.116,PGX_AM_BS_GSM514599,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.418000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,100,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa394,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviua3,pgxind-kftx4lae,pgxcs-kftwbrrq,358564667,0.125,195588220,0.068,162976447,0.057,PGX_AM_BS_GSM514602,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.423000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,89,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514602,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa398,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514606,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuaa,pgxind-kftx4lam,pgxcs-kftwbrtm,644175528,0.224,363880969,0.127,280294559,0.097,PGX_AM_BS_GSM514606,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.428000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,23,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa39a,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514608,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuad,pgxind-kftx4laq,pgxcs-kftwbrul,799390394,0.278,413779404,0.144,385610990,0.134,PGX_AM_BS_GSM514608,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.431000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,64,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa39b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuaf,pgxind-kftx4las,pgxcs-kftwbrv2,93812275,0.033,13215941,0.005,80596334,0.028,PGX_AM_BS_GSM514609,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.433000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,65,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,,,,geo:gsm,geo:GSM514609,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa39c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuag,pgxind-kftx4lau,pgxcs-kftwbrvk,114177637,0.04,86328489,0.03,27849148,0.01,PGX_AM_BS_GSM514610,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.434000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,6,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514610,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa39e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuak,pgxind-kftx4laz,pgxcs-kftwbrwi,840930325,0.292,335201587,0.117,505728738,0.176,PGX_AM_BS_GSM514612,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.437000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),,,,,,,,1,33,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514612,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa39f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviual,pgxind-kftx4lb1,pgxcs-kftwbrwz,1079572234,0.376,581236896,0.202,498335338,0.173,PGX_AM_BS_GSM514613,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.438000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),,,,,,,,1,30,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514613,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3a1,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514615,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuap,pgxind-kftx4lb4,pgxcs-kftwbrxy,562539945,0.196,285166582,0.099,277373363,0.096,PGX_AM_BS_GSM514615,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.442000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,81,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL9077,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3a6,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514643,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuax,pgxind-kftx4lbe,pgxcs-kftwbsbf,229802451,0.08,90083931,0.031,139718520,0.049,PGX_AM_BS_GSM514643,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.449000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,61,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3a8,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub0,pgxind-kftx4lbi,pgxcs-kftwbs1c,76077529,0.026,31722943,0.011,44354586,0.015,PGX_AM_BS_GSM514622,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.451000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,24,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,,,,geo:gsm,geo:GSM514622,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3a9,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub2,pgxind-kftx4lbk,pgxcs-kftwbs1t,412695829,0.144,150981618,0.053,261714211,0.091,PGX_AM_BS_GSM514623,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.453000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,1,31,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gpl,geo:gse,geo:GSE20483,,,,,,geo:gsm,geo:GSM514623,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3aa,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514624,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub3,pgxind-kftx4lbm,pgxcs-kftwbs2a,472390397,0.164,230864166,0.08,241526231,0.084,PGX_AM_BS_GSM514624,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.454000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,,,,,,,,1,87,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gse,geo:gpl,geo:GPL9077,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3ab,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub5,pgxind-kftx4lbo,pgxcs-kftwbs2s,223766526,0.078,84927900,0.03,138838626,0.048,PGX_AM_BS_GSM514625,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.456000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,41,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,,,,geo:gsm,geo:GSM514625,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3ac,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514626,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub7,pgxind-kftx4lbq,pgxcs-kftwbs39,669037597,0.233,413903762,0.144,255133835,0.089,PGX_AM_BS_GSM514626,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.457000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,21,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3ad,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviub8,pgxind-kftx4lbs,pgxcs-kftwbs3q,339446871,0.118,121835339,0.042,217611532,0.076,PGX_AM_BS_GSM514627,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.459000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,73,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gpl,geo:gse,geo:GSE20483,,,,,,geo:gsm,geo:GSM514627,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3b1,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviubf,pgxind-kftx4lc0,pgxcs-kftwbs5n,269675755,0.094,138085732,0.048,131590023,0.046,PGX_AM_BS_GSM514631,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.464000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,97,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,,,,geo:gsm,geo:GSM514631,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3b2,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviubh,pgxind-kftx4lc3,pgxcs-kftwbs64,612016258,0.213,367142136,0.128,244874122,0.085,PGX_AM_BS_GSM514632,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.466000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,82,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514632,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3b4,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514634,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviubk,pgxind-kftx4lc7,pgxcs-kftwbs73,28655108,0.01,18759785,0.007,9895323,0.003,PGX_AM_BS_GSM514634,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.468000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,94,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gse,geo:gpl,geo:GPL9077,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3b7,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE20483,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviubp,pgxind-kftx4lcd,pgxcs-kftwbs8j,1306768833,0.455,766953521,0.267,539815312,0.188,PGX_AM_BS_GSM514637,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.472000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),,,,,,,,1,52,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514637,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3bb,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviubv,pgxind-kftx4lcl,pgxcs-kftwbsag,474757239,0.165,314036622,0.109,160720617,0.056,PGX_AM_BS_GSM514641,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.478000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,80,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514641,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614409d374f2dc3aa3be,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514644,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuc1,pgxind-kftx4lcr,pgxcs-kftwbsbx,59279669,0.021,11042365,0.004,48237304,0.017,PGX_AM_BS_GSM514644,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.483000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,,,,,,,,1,60,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gse,geo:gpl,geo:GPL9077,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3c0,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514646,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuc4,pgxind-kftx4lcv,pgxcs-kftwbscw,128352403,0.045,6246518,0.002,122105885,0.042,PGX_AM_BS_GSM514646,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.485000,geo:GPL9077,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,45,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,,,,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3c3,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514649,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuc9,pgxind-kftx4ld1,pgxcs-kftwbsec,668142267,0.232,416034266,0.145,252108001,0.088,PGX_AM_BS_GSM514649,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.489000,geo:GPL9077,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,13,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gpl,geo:gse,geo:GSE20483,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3c4,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucb,pgxind-kftx4ld3,pgxcs-kftwbsfb,136444611,0.047,14479834,0.005,121964777,0.042,PGX_AM_BS_GSM514651,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.491000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,54,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514651,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3c5,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucd,pgxind-kftx4ld5,pgxcs-kftwbset,878886969,0.306,513372404,0.179,365514565,0.127,PGX_AM_BS_GSM514650,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.492000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,1,22,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514650,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3c7,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514652,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucg,pgxind-kftx4ld8,pgxcs-kftwbsfs,2022235497,0.703,1085923266,0.378,936312231,0.326,PGX_AM_BS_GSM514652,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.495000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,35,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE20483,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3ca,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514656,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucl,pgxind-kftx4lde,pgxcs-kftwbshq,44158851,0.015,9507999,0.003,34650852,0.012,PGX_AM_BS_GSM514656,{},11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.499000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-2021progenetix,Version at Progenetix Update 2021,,,,,,,,1,32,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gse,geo:GSE20483,,,,,,geo:gpl,geo:GPL9077,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3cc,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviuco,pgxind-kftx4ldi,pgxcs-kftwbsip,269332605,0.094,128593359,0.045,140739246,0.049,PGX_AM_BS_GSM514658,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.502000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,47,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL9077,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514658,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3cd,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucq,pgxind-kftx4ldk,pgxcs-kftwbsj6,106808152,0.037,6749403,0.002,100058749,0.035,PGX_AM_BS_GSM514659,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.503000,geo:GSE20483,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,1,12,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL9077,,,,,,geo:gsm,geo:GSM514659,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3d1,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM514663,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviucx,pgxind-kftx4lds,pgxcs-kftwbsmq,122642491,0.043,87711095,0.031,34931396,0.012,PGX_AM_BS_GSM514663,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.509000,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,18,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gse,geo:GSE20483,,,,,,geo:gpl,geo:GPL9077,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5c86614509d374f2dc3aa3d6,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL9077,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftviud5,pgxind-kftx4le2,pgxcs-kftwbsp4,764161541,0.266,360808836,0.125,403352705,0.14,PGX_AM_BS_GSM514668,,11.97,57.71,Point,SWE,Goeteborg,Sweden,"Goeteborg, Sweden",57.71,11.97,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:45:41.516000,geo:GSE20483,,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,23,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:20551037,"Parris TZ, Danielsson A et al. (2010): Clinical implications of gene dosage and...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM514668,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771b99,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtgm,pgxind-kftx5ruq,pgxcs-kftwmct3,242244705,0.084,109741887,0.038,132502818,0.046,PGX_AM_BS_GSM217396,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.902000,geo:GSE8757,,P46Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,5.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217396,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771b9c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtgr,pgxind-kftx5ruw,pgxcs-kftwmcu9,18663950,0.006,583063,0,18080887,0.006,PGX_AM_BS_GSM217399,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.905000,geo:GPL5737,,P55Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,7.08,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217399,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771ba3,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217406,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjth3,pgxind-kftx5rva,pgxcs-kftwmcx1,380512099,0.132,201611197,0.07,178900902,0.062,PGX_AM_BS_GSM217406,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.914000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P70Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,1.33,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771ba7,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjth9,pgxind-kftx5rvi,pgxcs-kftwmcym,287370876,0.1,95013520,0.033,192357356,0.067,PGX_AM_BS_GSM217410,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.919000,geo:GSE8757,,P43Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,6.25,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,,,,geo:gsm,geo:GSM217410,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771ba9,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217412,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthc,pgxind-kftx5rvm,pgxcs-kftwmczf,409249832,0.142,336507550,0.117,72742282,0.025,PGX_AM_BS_GSM217412,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.922000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P60Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,2.17,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771baa,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217413,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthe,pgxind-kftx5rvo,pgxcs-kftwmczt,634116939,0.221,343392236,0.119,290724703,0.101,PGX_AM_BS_GSM217413,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.923000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P58Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,2.33,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bab,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217414,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthg,pgxind-kftx5rvq,pgxcs-kftwmd08,74050083,0.026,44634996,0.016,29415087,0.01,PGX_AM_BS_GSM217414,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.925000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P58Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,6.5,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bad,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthj,pgxind-kftx5rvu,pgxcs-kftwmd10,596540266,0.207,401725443,0.14,194814823,0.068,PGX_AM_BS_GSM217416,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.927000,geo:GPL5737,,P70Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,5.25,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217416,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771baf,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217418,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthm,pgxind-kftx5rvy,pgxcs-kftwmd1t,265743198,0.092,214840031,0.075,50903167,0.018,PGX_AM_BS_GSM217418,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.930000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P63Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,8.08,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bb3,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217422,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtht,pgxind-kftx5rw7,pgxcs-kftwmd3e,199020516,0.069,90379355,0.031,108641161,0.038,PGX_AM_BS_GSM217422,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.935000,geo:GPL5737,,P57Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,8.25,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bb6,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjthy,pgxind-kftx5rwd,pgxcs-kftwmd4k,51727642,0.018,42117529,0.015,9610113,0.003,PGX_AM_BS_GSM217425,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.938000,geo:GSE8757,,P52Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,4.08,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217425,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bb7,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217426,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjti0,pgxind-kftx5rwf,pgxcs-kftwmd4y,861596235,0.3,606862095,0.211,254734140,0.089,PGX_AM_BS_GSM217426,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.940000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P53Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,5.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bba,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217429,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjti5,pgxind-kftx5rwl,pgxcs-kftwmd66,146704868,0.051,29833665,0.01,116871203,0.041,PGX_AM_BS_GSM217429,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.943000,geo:GSE8757,,P60Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,2.92,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bbc,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217431,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjti8,pgxind-kftx5rwp,pgxcs-kftwmd6y,112674298,0.039,960947,0,111713351,0.039,PGX_AM_BS_GSM217431,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.946000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P64Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,1.42,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bbe,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217433,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtic,pgxind-kftx5rwt,pgxcs-kftwmd7q,24152044,0.008,1395647,0,22756397,0.008,PGX_AM_BS_GSM217433,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.948000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P39Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,7.25,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bc0,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtif,pgxind-kftx5rwx,pgxcs-kftwmd8j,308027923,0.107,71404671,0.025,236623252,0.082,PGX_AM_BS_GSM217435,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.951000,geo:GSE8757,,P60Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,2.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217435,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bc2,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtii,pgxind-kftx5rx1,pgxcs-kftwmd9b,41252,0,17557,0,23695,0,PGX_AM_BS_GSM217437,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.953000,geo:GPL5737,,P45Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,7.83,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217437,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bc4,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtil,pgxind-kftx5rx5,pgxcs-kftwmda4,58477623,0.02,369768,0,58107855,0.02,PGX_AM_BS_GSM217439,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.956000,geo:GPL5737,,P63Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,3.5,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gpl,geo:gse,geo:GSE8757,,,,,,geo:gsm,geo:GSM217439,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bc8,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtis,pgxind-kftx5rxd,pgxcs-kftwmdbo,0,0,0,0,0,0,PGX_AM_BS_GSM217443,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.960000,geo:GSE8757,,P65Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,7.33,,,,,,,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,,,,geo:gsm,geo:GSM217443,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bc9,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217444,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtiu,pgxind-kftx5rxf,pgxcs-kftwmdc3,131322494,0.046,4521107,0.002,126801387,0.044,PGX_AM_BS_GSM217444,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.962000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P61Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,2.17,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bca,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtiv,pgxind-kftx5rxh,pgxcs-kftwmdch,41621676,0.014,40638649,0.014,983027,0,PGX_AM_BS_GSM217445,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.963000,geo:GPL5737,,P68Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,12.08,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217445,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bcd,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217448,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtj0,pgxind-kftx5rxn,pgxcs-kftwmddp,206827541,0.072,37316301,0.013,169511240,0.059,PGX_AM_BS_GSM217448,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.966000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P69Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,13,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bcf,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217450,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtj4,pgxind-kftx5rxq,pgxcs-kftwmdei,178705,0,0,0,178705,0,PGX_AM_BS_GSM217450,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.969000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P66Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,5.33,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gse,geo:GSE8757,,,,,,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bd0,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217451,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtj5,pgxind-kftx5rxs,pgxcs-kftwmdew,10708864,0.004,0,0,10708864,0.004,PGX_AM_BS_GSM217451,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.970000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P42Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,3.42,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,,,,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bd9,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217460,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtjk,pgxind-kftx5ryb,pgxcs-kftwmdk2,126777382,0.044,3945131,0.001,122832251,0.043,PGX_AM_BS_GSM217460,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.981000,geo:GSE8757,,P57Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,6.5,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bdd,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217464,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtjr,pgxind-kftx5ryk,pgxcs-kftwmdlo,0,0,0,0,0,0,PGX_AM_BS_GSM217464,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.986000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P56Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,9.25,,,,,,,geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,,,,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bde,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217465,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtjt,pgxind-kftx5rym,pgxcs-kftwmdm2,12152323,0.004,1634160,0.001,10518163,0.004,PGX_AM_BS_GSM217465,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.987000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P41Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,9,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bdf,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtju,pgxind-kftx5ryo,pgxcs-kftwmdmg,896274867,0.312,506628037,0.176,389646830,0.136,PGX_AM_BS_GSM217466,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.988000,geo:GSE8757,,P68Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,11,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217466,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be1,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtjy,pgxind-kftx5rys,pgxcs-kftwmdn9,26141601,0.009,564912,0,25576689,0.009,PGX_AM_BS_GSM217468,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.991000,geo:GSE8757,,P67Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,8.25,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217468,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be2,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtjz,pgxind-kftx5ryu,pgxcs-kftwmdnn,67964068,0.024,3211690,0.001,64752378,0.023,PGX_AM_BS_GSM217469,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.992000,geo:GPL5737,,P55Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,2.33,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217469,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be3,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217470,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtk1,pgxind-kftx5ryw,pgxcs-kftwmdo1,11740638,0.004,5507697,0.002,6232941,0.002,PGX_AM_BS_GSM217470,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.993000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P66Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,2.5,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,,,,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be4,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtk3,pgxind-kftx5ryy,pgxcs-kftwmdof,70788768,0.025,37693375,0.013,33095393,0.012,PGX_AM_BS_GSM217471,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.994000,geo:GPL5737,,P53Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,2.25,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217471,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be5,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtk4,pgxind-kftx5rz0,pgxcs-kftwmdou,615555283,0.214,344191276,0.12,271364007,0.094,PGX_AM_BS_GSM217472,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:20.996000,geo:GSE8757,,P58Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,1.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217472,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771be9,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtkb,pgxind-kftx5rz9,pgxcs-kftwmdqf,794571,0,253116,0,541455,0,PGX_AM_BS_GSM217476,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},10.09.20 17:46,geo:GPL5737,,P63Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,1.42,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,,,,geo:gsm,geo:GSM217476,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bec,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217479,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtkg,pgxind-kftx5rzf,pgxcs-kftwmdrm,1742398,0.001,1654543,0.001,87855,0,PGX_AM_BS_GSM217479,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.004000,geo:GSE8757,,P68Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,6,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bee,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtkj,pgxind-kftx5rzj,pgxcs-kftwmdsf,4482680,0.002,2650490,0.001,1832190,0.001,PGX_AM_BS_GSM217481,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.006000,geo:GSE8757,,P47Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,9.33,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217481,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bf2,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtkp,pgxind-kftx5rzr,pgxcs-kftwmdu1,14343652,0.005,1817781,0.001,12525871,0.004,PGX_AM_BS_GSM217485,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.011000,geo:GSE8757,,P59Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,5.08,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,,,,geo:gsm,geo:GSM217485,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bfe,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtl9,pgxind-kftx5s0g,pgxcs-kftwmdyt,119576509,0.042,0,0,119576509,0.042,PGX_AM_BS_GSM217497,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.026000,geo:GPL5737,,P53Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,1.5,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217497,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771bff,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217498,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtla,pgxind-kftx5s0i,pgxcs-kftwmdz7,6608600,0.002,2151981,0.001,4456619,0.002,PGX_AM_BS_GSM217498,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.027000,geo:GSE8757,,P40Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,3.08,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,,,,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c02,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217501,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtlf,pgxind-kftx5s0o,pgxcs-kftwme0e,1676069,0.001,1665878,0.001,10191,0,PGX_AM_BS_GSM217501,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.031000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P54Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,7.5,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,pubmed,geo:gpl,geo:GPL5737,,,,,,geo:gse,geo:GSE8757,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c05,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217504,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtlk,pgxind-kftx5s0u,pgxcs-kftwme1m,93561652,0.033,523711,0,93037941,0.032,PGX_AM_BS_GSM217504,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.034000,geo:GPL5737,,P56Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,1.58,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gpl,geo:gse,geo:GSE8757,,,,,,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c0e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217513,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtlz,pgxind-kftx5s1d,pgxcs-kftwme57,159242598,0.055,43494375,0.015,115748223,0.04,PGX_AM_BS_GSM217513,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.045000,geo:GSE8757,,P62Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,7.92,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c0f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217514,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtm0,pgxind-kftx5s1f,pgxcs-kftwme5m,1218582,0,344407,0,874175,0,PGX_AM_BS_GSM217514,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.046000,geo:GSE8757,,P60Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,8.08,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c14,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtm9,pgxind-kftx5s1p,pgxcs-kftwme7k,46843606,0.016,5074884,0.002,41768722,0.015,PGX_AM_BS_GSM217519,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.052000,geo:GSE8757,,P53Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,9.33,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL5737,,,,,,geo:gsm,geo:GSM217519,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c19,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtmh,pgxind-kftx5s1z,pgxcs-kftwme9l,305106623,0.106,91368522,0.032,213738101,0.074,PGX_AM_BS_GSM217524,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.058000,geo:GPL5737,,P64Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,4.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217524,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c1b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtmk,pgxind-kftx5s23,pgxcs-kftwmeae,2452536,0.001,1699206,0.001,753330,0,PGX_AM_BS_GSM217526,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.061000,geo:GPL5737,,P47Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,6.25,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gpl,geo:gse,geo:GSE8757,,,,,,geo:gsm,geo:GSM217526,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c23,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217534,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtmx,pgxind-kftx5s2k,pgxcs-kftwmedl,643175,0,120130,0,523045,0,PGX_AM_BS_GSM217534,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.070000,geo:GPL5737,,P57Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,8.33,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gpl,geo:gse,geo:GSE8757,,,,,,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c24,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217535,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtmz,pgxind-kftx5s2m,pgxcs-kftwmedz,245716501,0.085,35465154,0.012,210251347,0.073,PGX_AM_BS_GSM217535,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.072000,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",P65Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,1.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,pubmed,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gpl,geo:GPL5737,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c28,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtn6,pgxind-kftx5s2u,pgxcs-kftwmefk,656737448,0.228,516874060,0.18,139863388,0.049,PGX_AM_BS_GSM217539,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.076000,geo:GSE8757,,P58Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,3.58,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217539,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c2a,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtn9,pgxind-kftx5s2y,pgxcs-kftwmegd,1118751,0,1118751,0,0,0,PGX_AM_BS_GSM217541,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.079000,geo:GSE8757,,P69Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,5.08,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),pubmed,geo:gse,geo:gpl,geo:GPL5737,,,,,,geo:gsm,geo:GSM217541,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c33,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217550,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtno,pgxind-kftx5s3g,pgxcs-kftwmejx,110440766,0.038,325172,0,110115594,0.038,PGX_AM_BS_GSM217550,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.090000,geo:GSE8757,,P70Y,pgxcohort-2021progenetix,Version at Progenetix Update 2021,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,2.25,,,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,,,,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c36,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSE8757,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtns,pgxind-kftx5s3m,pgxcs-kftwmel3,213779605,0.074,79306699,0.028,134472906,0.047,PGX_AM_BS_GSM217553,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.094000,geo:GPL5737,,P70Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,1,5.83,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gse,geo:gpl,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217553,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c38,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GSM217555,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtnw,pgxind-kftx5s3q,pgxcs-kftwmelv,159645401,0.056,79693,0,159565708,0.056,PGX_AM_BS_GSM217555,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.096000,geo:GSE8757,,P62Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,2.58,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gsm,geo:gse,geo:gpl,geo:GPL5737,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c3d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjto4,pgxind-kftx5s41,pgxcs-kftwment,107163325,0.037,73168,0,107090157,0.037,PGX_AM_BS_GSM217560,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.102000,geo:GSE8757,,P52Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,7.83,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217560,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c41,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtob,pgxind-kftx5s49,pgxcs-kftwmepe,7422497,0.003,1711830,0.001,5710667,0.002,PGX_AM_BS_GSM217564,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.107000,geo:GPL5737,,P55Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,1,4.83,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,pubmed,geo:gpl,geo:gse,geo:GSE8757,,,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217564,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F
5dc17b4c09d374f6dd771c42,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,breast carcinoma,geo:GPL5737,,NCIT:C4017,Ductal Breast Carcinoma,icdom-85003,"Infiltrating duct carcinoma, NOS",icdot-C50.9,"Breast, NOS",pgxbs-kftvjtod,pgxind-kftx5s4b,pgxcs-kftwmeps,7395732,0.003,1716680,0.001,5679052,0.002,PGX_AM_BS_GSM217565,,-0.13,51.51,Point,GBR,London,United Kingdom,"London, United Kingdom",51.51,-0.13,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000310,breast,{},2020-09-10 17:46:21.108000,geo:GSE8757,,P68Y,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,1,6.75,,,,,pgxcohort-2021progenetix,Version at Progenetix Update 2021,geo:gpl,geo:gse,pubmed,PMID:17925008,"Chin SF, Teschendorff AE et al. (2007): High-resolution aCGH and expression profiling identifies...",,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),,geo:gsm,geo:GSM217565,,arraymap import,,,,,,,,,,,,,,,,,,,,,,,F